Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes
Abdulla A. Damluji, Director of the Cardiovascular Center on Aging at Cleveland Clinic, has shared a post on X:
“Check out my latest article: Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease via LinkedIn”
Title: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Authors: Stephen J. Nicholls, Imre Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, A. Michael Lincoff, Darren K. McGuire, Debra Miller, Michael A. Nauck, Hiroshi Nishiyama, Steven E. Nissen, Naveed Sattar, Govinda Weerakkody, Russell J. Wiese, Bernard Zinman, Sophia Zoungas, Jan Basile, Melanie J. Davies, Francesco Giorgino, Monika Kellerer, Linong Ji, Tamas Varkonyi, Venu Menon, Jonathan C. Broder, Alan Herschtal, David D’Alessio, Eli Lilly and Company, SURPASS-CVOT Investigators
Discover the latest in Hemostasis Today.
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC
-
Apr 9, 2026, 18:21New Clinical Practice Guideline on Anticoagulant Prophylaxis in Pediatric Patients at Risk of VTE – ISTH